Boehringer Ingelheim Press Releases

Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio

Sustained viral response achieved in 83% of hepatitis C infected patients with new HCV protease inhibitor from Boehringer Ingelheim

U.S. FDA approves once-daily Viramune® XR™ tablet for use in combination with other antiretroviral agents for treatment of HIV-1 infection in adults

Boehringer Ingelheim finalizes acquisition of AMGEN’s Fremont facility in the USA

Dabigatran etexilate is cost-effective for stroke prevention in atrial fibrillation, particularly in real-world clinical practice

The POET-COPD® study results demonstrate superiority of Spiriva® (tiotropium) over long-acting beta agonist salmeterol in reducing the risk for COPD exacerbations

Survey of people with atrial fibrillation and their doctors uncovers need for more education about the link between AF and stroke

Actress Jane Seymour takes up the fight against common heart rhythm disorder, atrial fibrillation and its link to stroke

Mixing claim approved for Mycoplasma vaccine from Boehringer Ingelheim

MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim

Porcine Circovirus remains in the spotlight of European researchers

Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the use of Pfēnex Expression Technology™

Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement for Elan’s Antibody-Based Therapeutics Pipeline

PRAZAXA® (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation

Boehringer Ingelheim to Purchase Amgen’s Fremont (USA) Facility

EPIC trial with pimobendan* examines delay of congestive heart failure in dogs

Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide